Holen Sie sich die Stockscreener-App
0.2932
2.95%
-0.0089
Handel nachbörslich:
.29
-0.0032
-1.09%
Schlusskurs vom Vortag:
$0.3021
Offen:
$0.3
24-Stunden-Volumen:
603.32K
Relative Volume:
0.37
Marktkapitalisierung:
$13.76M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-37.75M
KGV:
-0.0902
EPS:
-3.25
Netto-Cashflow:
$-30.91M
1W Leistung:
-18.60%
1M Leistung:
+6.15%
6M Leistung:
-86.43%
1J Leistung:
-92.63%
1-Tages-Spanne:
$0.2909
$0.3128
1-Wochen-Bereich:
$0.2899
$0.369
52-Wochen-Spanne:
$0.224
$4.1499
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Firmenname
Cellectar Biosciences Inc
Sektor
Branche
Telefon
(608) 441-8120
Adresse
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Vergleichen Sie CLRB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
0.2932 | 13.76M | 0 | -37.75M | -30.91M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 125.55B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 67.78B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 36.24B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.99B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.77B | 3.81B | -644.79M | -669.77M | -6.24 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-05 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2020-07-01 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-21 | Fortgesetzt | ROTH Capital | Buy |
| 2019-09-13 | Eingeleitet | ROTH Capital | Buy |
| 2016-12-21 | Eingeleitet | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc Aktie (CLRB) Neueste Nachrichten
Cellectar Biosciences (NASDAQ:CLRB) Coverage Initiated at StockNews.com - Defense World
Financial Contrast: Cellectar Biosciences (NASDAQ:CLRB) versus Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World
Cellectar Biosciences (NASDAQ:CLRB) Now Covered by StockNews.com - Defense World
Cellectar Biosciences (CLRB) to Release Earnings on Wednesday - Defense World
Is Cellectar Biosciences (CLRB) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
StockNews.com Begins Coverage on Cellectar Biosciences (NASDAQ:CLRB) - Defense World
Cellectar Biosciences Enhances CEO and COO Severance Benefits - TipRanks
What is Roth Capital’s Estimate for CLRB FY2029 Earnings? - Defense World
Earnings call transcript: Cellectar Biosciences Q4 2024 sees restructuring amid losses - Investing.com Australia
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2024 Earnings Call Transcript - Insider Monkey
Cellectar Biosciences Inc (CLRB) Q4 2024 Earnings Call Highlights: Strategic Restructuring and ... - Yahoo Finance
Cellectar Biosciences Inc (CLRB) Q4 2024 Earnings Call Highlight - GuruFocus.com
Cellectar Biosciences Faces Financial and Legal Turmoil Amidst Restated Earnings - TipRanks
Cellectar Biosciences Advances Cancer Drug Pipeline - TipRanks
Cellectar Biosciences Earnings Call: Mixed Outlook Amid Successes and Challenges - TipRanks
Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update - GlobeNewswire
Cellectar's Breakthrough: 83.6% Response Rate Puts FDA Fast Track Within Reach - StockTitan
Cellectar Biosciences Provides Update on FDA Regulatory Path for Iopofosine I 131 in Waldenström Macroglobulinemia and Advances Phase 1 Trials for New Radioconjugates - Nasdaq
Cellectar Biosciences COO acquires $8,400 in stock By Investing.com - Investing.com Canada
Cellectar Biosciences COO acquires $8,400 in stock - Investing.com India
Cellectar Biosciences to Present at the 37th Annual Roth Conference - Quantisnow
Cellectar Biosciences Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Cellectar Biosciences, Inc. to Present at 37th Annual Roth Conference - Nasdaq
Cancer Treatment Breakthrough? Cellectar Biosciences Reveals Latest Progress at Major Investor Conference - StockTitan
Before You Invest, Make Sure You Check This Cellectar Biosciences Inc (NASDAQ: CLRB) Analysis - stocksregister.com
Cellectar Biosciences (NASDAQ:CLRB) Now Covered by Analysts at StockNews.com - Defense World
Cellectar Biosciences (CLRB) Expected to Announce Quarterly Earnings on Thursday - Defense World
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025 - GlobeNewswire
Cellectar Biosciences, Inc. to Report 2024 Financial Results and Corporate Update on March 13, 2025 - Nasdaq
When Will Cellectar Biosciences Reveal Its 2024 Financial Performance? - StockTitan
StockNews.com Initiates Coverage on Cellectar Biosciences (NASDAQ:CLRB) - Defense World
CLRB’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Prepare Yourself for Liftoff: Cellectar Biosciences Inc (CLRB) - SETE News
SEC Form 424B3 filed by Cellectar Biosciences Inc. - Quantisnow
A look into Cellectar Biosciences Inc (CLRB)’s deeper side - SETE News
Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Cellectar Biosciences, Inc. to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 - Nasdaq
Cellectar Biosciences Showcases Cancer Treatment Pipeline at Major Healthcare Conference - StockTitan
Examining Cellectar Biosciences Inc (CLRB) stock is warranted - US Post News
Cellectar faces Nasdaq delisting over share price rule - MSN
Market Momentum Report: Cellectar Biosciences Inc (CLRB)’s Positive Close at 0.26 - The Dwinnex
Finanzdaten der Cellectar Biosciences Inc-Aktie (CLRB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):